PUBLISHER: The Business Research Company | PRODUCT CODE: 1409511
PUBLISHER: The Business Research Company | PRODUCT CODE: 1409511
“Immunohistochemistry (IHC) Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on immunohistochemistry (hick) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for immunohistochemistry (hick)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The immunohistochemistry (hick) market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Immunohistochemistry (IHC) is a diagnostic technique that utilizes the interaction between antibodies and antigens to identify specific proteins and antigens within tissue sections. This interaction is visualized through chromogenic detection using enzyme-substrate or fluorescent detection using fluorescent dyes.
The main products associated with immunohistochemistry (IHC) include antibodies, equipment, reagents, and kits. Antibodies are proteins produced by the immune system to neutralize harmful antigens, and in the context of IHC, they are employed to detect the specific location of proteins or antigens for diagnostic purposes. The applications of IHC span diagnostics, drug testing, and other related areas, with end-users including hospitals, diagnostic laboratories, research institutes, and others.
The immunohistochemistry (IHC) market research report is one of a series of new reports from The Business Research Company that provides immunohistochemistry (IHC) market statistics, including immunohistochemistry (IHC) industry global market size, regional shares, competitors with a immunohistochemistry (IHC) market share, detailed immunohistochemistry (IHC) market segments, market trends and opportunities, and any further data you may need to thrive in the immunohistochemistry (IHC) industry. This immunohistochemistry (IHC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The immunohistochemistry (ihc) market size has grown strongly in recent years. It will grow from $2.43 billion in 2023 to $2.65 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth observed in the historical period can be attributed to several factors, including increased clinical adoption of immunohistochemistry (IHC), industry standardization practices, expansion in cancer research, the automation of laboratory processes, and advancements in clinical diagnostics.
The immunohistochemistry (ihc) market size is expected to see strong growth in the next few years. It will grow to $3.77 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be attributed to factors such as the entry of new players into the market, increased demand in drug development, integration of immunohistochemistry (IHC) in biomedical research, expanding applications in diagnostics, and the ongoing trends of automation and digitalization in laboratory processes. Major trends expected in the forecast period include the adoption of multiplex IHC techniques, integration with digital pathology systems, improvements in antibody specificity, increased automation and standardization of IHC processes, and the application of IHC in biomarker discovery.
The immunohistochemistry (IHC) market is anticipated to witness growth due to the increasing prevalence of chronic diseases. Chronic diseases, lasting for extended periods and typically manageable but not curable, include conditions such as cancer and cardiovascular disorders. Immunohistochemistry is crucial in diagnosing these diseases, offering advantages such as specificity, sensitivity to detect specific antigens, and rapid results. In 2022, the Centers for Disease Control and Prevention reported that approximately 37.3 million people in the United States, accounting for 11.3% of the population, have diabetes, emphasizing the role of immunohistochemistry in addressing the rising burden of chronic diseases.
The growth of the immunohistochemistry (IHC) market is further driven by the increasing demand for personalized medicines. Personalized medicine tailors medical decisions and interventions based on individual patients' unique genetic, environmental, and lifestyle characteristics. Immunohistochemistry plays a significant role in this context, detecting specific protein markers crucial for accurate tumor classification and diagnosis. The Personalized Medicine Coalition projected that over 75,000 genetic testing products and 300 personalized medicines will be available for various diseases, reinforcing the pivotal role of immunohistochemistry in advancing personalized medicine.
Technological advancement stands out as a key trend in the immunohistochemistry (IHC) market, with major companies focusing on developing advanced products. For example, Akoya Biosciences introduced the Opal Multiplex Detection Kits, utilizing Opal multiplex technology for detecting multiple biomarkers in tissue sections. These kits offer phenotypic scoring, signal amplification, low sample and reagent consumption, and the ability to measure 3 to 8 IHC targets and nuclear stains.
Major companies in the immunohistochemistry (IHC) market are introducing innovative platforms, such as automated staining platforms, to enhance IHC applications. These platforms automate the staining process of tissue sections with antibodies, improving efficiency and accuracy. Biocare Medical LLC launched the ONCORE Pro Automated Slide Staining System in January 2021, providing a fully automated platform for IHC and in-situ hybridization (ISH) applications. The system can process up to 36 slides in a single run, enabling high-throughput slide processing for diagnostic laboratories.
In October 2021, StageBio, a US-based company specializing in immunohistochemistry (IHC), acquired TPL Path Labs. This acquisition aims to strengthen StageBio's product portfolio in IHC, clinical histopathology, and molecular pathology, enhancing its market position. TPL Path Labs, based in Germany, operates in the field of immunohistochemistry (IHC).
Major companies operating in the immunohistochemistry (ihc) market report are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, The Merck Group, Danaher Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Bio SB Inc., Agilent Technologies Inc., Abcam plc, Becton Dickinson and Company, Takara Bio Inc., Biocare Medical LLC, Bio-Genex Laboratories, Diagnostic BioSystems Inc., BioVision Inc., PHC Holdings Corporation, Abbott Laboratories, Leica Biosystems, Vector Laboratories, Indivumed GmbH, Qritive, Ionpath Inc., Reveal Biosciences, Akrivis Technologies Private Limited, LifeSpan BioSciences Inc., Enzo Life Sciences Inc., Epitomics Inc., GenScript Biotech, Histologix Ltd., NeoGenomics Laboratories Inc
North America was the largest region in the immunohistochemistry (IHC) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the immunohistochemistry (IHC) market report during the forecast period. The regions covered in the immunohistochemistry (ihc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the immunohistochemistry (ihc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The immunohistochemistry (IHC) market consists of sales of primary antibodies, slide staining system, tissue microarrays, tissue processing systems, slide scanners secondary antibodies, histological stains, blocking sera and reagents, chromogenic substrates, fixation reagents and stabilizers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.